Li Shuang, Zhang Jiayi, Sun Luyao, Yang Ze, Liu Xinxing, Liu Jianling, Liu Xifu
Ministry of Education Key Laboratory of Molecular and Cellular Biology, Hebei Anti-Tumour Molecular Target Technology Innovation Center, College of Life Science, Hebei Normal University, Shijiazhuang, China.
Jianyuan Precision Medicines (Zhangjiakou) Co., Ltd., Zhangjiakou, China.
Front Cell Dev Biol. 2025 Aug 18;13:1626996. doi: 10.3389/fcell.2025.1626996. eCollection 2025.
Extracellular vesicles (EVs), nanoscale vesicles released by various cell types, have garnered significant attention in regenerative medicine. Mesenchymal stem cell-derived EVs (MSC-EVs) exhibit unique advantages, including their compact size, ability to traverse the blood-brain barrier (BBB), low immunogenicity, and high biosafety profile. However, challenges such as standardization of isolation protocols, establishment of quality control criteria, and scalability of production remain unresolved. This review critically examines the methodologies for preparation, characterization, and pharmacokinetic profiling of MSC-EVs, alongside their therapeutic potential in neurological disorders. By synthesizing current advancements, this work aims to elucidate the translational value of EVs in clinical practice. Additionally, it seeks to accelerate their transition from preclinical research to therapeutic applications, and provide a robust theoretical foundation for novel strategies in treating neurological diseases.
细胞外囊泡(EVs)是由各种细胞类型释放的纳米级囊泡,在再生医学中受到了广泛关注。间充质干细胞衍生的细胞外囊泡(MSC-EVs)具有独特的优势,包括尺寸紧凑、能够穿越血脑屏障(BBB)、免疫原性低以及生物安全性高。然而,诸如分离方案的标准化、质量控制标准的建立以及生产的可扩展性等挑战仍未得到解决。本综述批判性地研究了MSC-EVs的制备、表征和药代动力学分析方法,以及它们在神经系统疾病中的治疗潜力。通过综合当前的进展,这项工作旨在阐明EVs在临床实践中的转化价值。此外,它旨在加速EVs从临床前研究向治疗应用的转变,并为治疗神经系统疾病的新策略提供坚实的理论基础。